Literature DB >> 3114547

[Decrease of serum lipoproteins and increase in apolipoproteins A-I and A-II following oral administration of multiple unsaturated phospholipids. Observations on the effect of nutrition on the results].

W Spann, G Wolfram, N Zöllner.   

Abstract

Polyenylphosphatidylcholine was given orally in a dosage of 10 g per day to 10 healthy subjects for 4 weeks. The concentrations of cholesterol, triglycerides, phospholipids, apolipoproteins AI, AII, and B were measured in serum, as were very low density lipoproteins, low density lipoproteins, and high density lipoproteins every 3 h on the day before and after the 4 weeks of application. The diet was controlled 10 days before and during the experiment using the dietary recall method. The evaluation of the diet records showed that 5 subjects had increased and 5 subjects had decreased their fat consumption in exchange for carbohydrates during the experiment. Nevertheless body weight remained constant within +/- 1 kg. Cholesterol in serum and low density lipoprotein decreased, but the differences were not statistically significant. In spite of dietary changes apolipoprotein AI and AII in high density lipoproteins increased significantly. We conclude that the influence of drugs on serum lipids can only be evaluated in conjunction with reliable control of the diet.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3114547     DOI: 10.1007/bf01726664

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  20 in total

1.  Metabolic regulation of plasma high density lipoprotein concentrations.

Authors:  E A Nikkila
Journal:  Eur J Clin Invest       Date:  1978-06       Impact factor: 4.686

2.  [Action of "essential" phospholipids on plasma lipids and fatty acids in type II hyperlipoproteinemias].

Authors:  H Peeters; V Blaton; F Soetewey; B Declercq; D Vandamme
Journal:  Munch Med Wochenschr       Date:  1973-08-03

3.  The contrasting effects of a dietary soya lecithin product and corn oil on lipoprotein lipids in normolipidemic and familial hypercholesterolemic subjects.

Authors:  M T Childs; J A Bowlin; J T Ogilvie; W R Hazzard; J J Albers
Journal:  Atherosclerosis       Date:  1981 Jan-Feb       Impact factor: 5.162

4.  Influence of oral polyunsaturated and saturated phospholipid treatment on the lipid composition and fatty acid profile of chimpanzee lipoproteins.

Authors:  M Rosseneu; B Declercq; D Vandamme; R Vercaemst; F Soetewey; H Peeters; V Blaton
Journal:  Atherosclerosis       Date:  1979-02       Impact factor: 5.162

5.  Effect of polyenephosphatidylcholine on cholesterol uptake by human high density lipoprotein.

Authors:  O Zierenberg; G Assmann; G Schmitz; M Rosseneu
Journal:  Atherosclerosis       Date:  1981-07       Impact factor: 5.162

6.  Postprandial effects of dietary phosphatidylcholine on plasma lipoproteins in man.

Authors:  P Simonsson; A Nilsson; B Akesson
Journal:  Am J Clin Nutr       Date:  1982-01       Impact factor: 7.045

7.  Intestinal absorption of polyenephosphatidylcholine in man.

Authors:  O Zierenberg; S M Grundy
Journal:  J Lipid Res       Date:  1982-11       Impact factor: 5.922

8.  The effect of polyunsaturated phosphatidylcholine on plasma lipids and fecal sterol excretion.

Authors:  H Greten; H Raetzer; A Stiehl; G Schettler
Journal:  Atherosclerosis       Date:  1980-05       Impact factor: 5.162

9.  [Dietary interview. I. Comparison between dietary history versus repeated daily recalls].

Authors:  H Karst; M Möhr; B Seppelt
Journal:  Nahrung       Date:  1979

10.  Acute effects of the pattern of fat ingestion on plasma high density lipoprotein components in man.

Authors:  R M Kay; S Rao; C Arnott; N E Miller; B Lewis
Journal:  Atherosclerosis       Date:  1980-08       Impact factor: 5.162

View more
  1 in total

1.  [Effects of equal amounts of linoleic acid in orally administered, polyunsaturated phospholipids or in safflower oil on blood lipoproteins].

Authors:  W Spann; G Wolfram; N Zöllner
Journal:  Klin Wochenschr       Date:  1987-10-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.